The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition

Table of Contents

Chapter 1: Executive Summary

• Figure 1-1: Molecular Point-of-Care Market (mPOC), 2023-2028 ($M)
• Figure 1-2: Near Patient Molecular Systems Market, 2023-2028 ($M)

Where is Molecular Point-of-Care in 2024?

• Table 1-1: Molecular Point-of-Care Market, 2023-2028 ($M)

Molecular Point-of-Care Market Analysis

Table 1-2: Molecular Point-of-Care Market Growth, 2023-2028 (%)

• Figure 1-3: mPOC Market by Disease Indication, 2023 (%; Respiratory, Other)

Market Observations

“Near-Patient” Molecular Systems Market

• Table 1-3: Near Patient Molecular Systems Market, 2023-2028 ($M)
• Table 1-4: Near Patient Molecular Systems Market Growth, 2023-2028 (%)
• Figure 1-4: mPOC and Near-Patient Market, 2023-2028 ($M)
• Table 1-5: mPOC and Near-Patient Market, 2023-2028 ($M)

Current Trends

Molecular Point-of-Care Diagnostics Defined

Usage of Molecular Point-of-Care

Leading mPOC Platforms

• Table 1-6: Molecular POC Diagnostic Platforms and Technologies

Trends

Scope and Methodology

Chapter 2: Molecular Point-of-Care Market Development and Trends

COVID-19 and Molecular POC

• Table 2-1: Molecular POC COVID-19 Emergency Authorizations

CDC Initial Response, Long Term Situation

COVID-19’s Unique Challenge

BARDA Directs Funding to mPOC

Regulatory Developments

Consortia, Funding, Prizes

Deals

• Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2024

Advantages and Disadvantages of Molecular Point-of-Care

• Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting (Physician Office Laboratory (POL) /  Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC)

Justification: The Sensitivity/Specificity Argument

New Systems and Menu Expansion

Mesa Biotech Strep A Approval

Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV

STI Continues to Be a Growth Area

Deals, Investment in mPOC Systems

Roche Acquires LumiraDx for up to $350M

Thermo Acquires Mesa Biotech

EU Researchers Awarded €3M to Develop POC Molecular Tests

Scope Fluidics AST System Sees Investment

China as a POC Market

Common Tests and Analytes in POC Diagnostics

Component Technologies of Molecular Point-of-Care Diagnostics

Microfluidics

qPCR

Microarrays

Isothermal Amplification

Test Automation

Primers and Probes

Detection

Next-Generation Sequencing

Molecular Diagnostics

Real-Time PCR (qPCR)

Isothermal Amplification Methods

Line Probe Assays

Next-Generation Sequencing

Applications and Potential Applications for Molecular Point-of-Care

Major Testing Applications for Molecular POC Diagnostics

Influenza

Reclassification of RIDTs

Hospital-Acquired Infections (HAIs)

Strep A

Respiratory Syncytial Virus (RSV)

Emerging Applications

Zika

Other Respiratory Infections

Group B Streptococcus

Human Papillomavirus

Herpes Simplex Virus

Vaginitis

Tuberculosis

Malaria

Other Tropical and Neglected Diseases

Cancer

European Device Regulations

Chapter 3: Market Analysis

Molecular Point-of-Care Market Analysis

• Table 3-1: Molecular Point-of-Care Market, 2023-2028 ($M, %)
• Figure 3-1: Molecular Point-of-Care Market, 2023-2028 ($M)
• Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region (North America, Europe, APAC, RoW), 2023 ($M, %)
• Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Area (COVID-Respiratory vs. Other), 2023 ($M, %)
• Figure 3-2: Breakout of Molecular Point-of-Care Market (Respiratory, Other), 2023 (%)

“Near Patient Molecular” Market

• Table 3-4: Near Patient Molecular Systems Market, 2023-2028 ($M, %)

Market Share Near Patient

• Figure 3-3:  Market Share, Near Patient Molecular Testing
• Table 3-5: Market Share, Near Patient Molecular Testing, by Vendor (Abbott, bioMérieux, Cepheid, Roche, Other), 2023 (%)

Chapter 4: Company Profiles

Abbott Laboratories

Aidian Oy

Akonni Biosystems

binx health, inc.

Biocartis NV

bioMérieux SA

• Table 4-1: bioMérieux FilmArray Est. Systems per Quarter, Q4 ’18-Q3 ’23
• Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q3 2022

Cepheid (Danaher)

Molecular Healthcare-Acquired Infection (HAI) Testing

Molecular Sexual Health and Women’s Health Testing

Molecular Critical Infectious Disease Testing

Molecular Oncology/Genetics Testing

Credo Diagnostics Biomedical Pte. Ltd.

Cue Health

Curetis NV (OpGen)

DiaSorin S.p.A

GenMark Diagnostics (Roche)

Greiner Bio-One GmbH

Lucira Health (Pfizer)

Meridian Bioscience, Inc. (SD Biosensor)

Mesa Biotech, Inc. (Thermo)

QIAGEN NV

QuantuMDx Group

QuidelOrtho Corporation

Roche

Sekisui Diagnostics LLC

T2 Biosystems